The trajectory of Viagra presents a intricate picture for investors. While the initial release here generated substantial returns, the lapse of its intellectual property protection opened the door to off-brand competitors, dramatically eroding sales. This presents a specific dilemma for pharmaceutical companies depending on comparable blockbuster m

The story of Viagra, and its parent company copyright, presents a intriguing case study for investors. Originally a blockbuster drug, generating billions in sales , its exclusivity period created a flood of generic competition , significantly impacting its position . While some firms may try to capitalize on male sexual dysfunction, the present lan